Filing Flows › Allogene Therapeutics (ALLO) › Recalls, complaints & regulation
Allogene Therapeutics (ALLO): clinical trials
Allogene Therapeutics (ALLO) beyond its filings: 5 active clinical trials.
Allogene Therapeutics' latest quarter
Allogene Therapeutics, Q2 2026: revenue $4.6M, net loss $42.7M, operating cash flow −$32.0M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Allogene Therapeutics have?
5 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.